Cancer diagnostics developer VolitionRx has reported positive preliminary results from a proof of concept clinical study of its Nu.Q assays to detect high-grade prostate cancer.

Nu.Q involves a series of blood tests to identify ‘very early’ nucleosomic markers of cancer, before the spread of the disease.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

“Data showed that the panel of five assays detected 94% of high-grade prostate cancers requiring therapy, with 88% specificity, compared to 33% identified using PSA alone.”

A panel of five assays with one prostate-specific antigen (PSA), two Nu.Q assays and two inflammatory biomarkers, was evaluated during the study.

Data showed that the panel detected 94% of high-grade prostate cancers requiring therapy, with 88% specificity, compared to 33% identified using PSA alone.

Volition chief scientific officer Jake Micallef said: “Based on this data, we believe that this test could assist clinicians in more accurate patient selection for prostate biopsy and treatment and substantially reduce the amount of unnecessary procedures in men with low-grade tumours or no tumour.”

Blood samples for the study were obtained from men referred for prostate biopsy in three Belgian hospitals.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The men were grouped by biopsy findings – no cancer, low-grade cancer or high-grade cancer, and the samples were analysed using the five assay panel.

Findings indicate that the assays may provide better risk stratification for men with actual or suspected prostate cancer. This could help in improved patient management and lower unnecessary biopsies.

Volition intends to validate these results in independent larger clinical trials, with plans to commercially introduce the Nu.Q assay products next year.

Volition CEO Cameron Reynolds said: “This small trial is important because it helps demonstrate once more the potential breadth of our technology.

“If these results are validated in larger trials, they will present a potentially significant new market opportunity.”

Medical Device Network Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Medical Device Network Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving medical devices advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now